Web Desc
HIV Persistence: Pathogenesis and Eradication
joint with HIV Vaccines
Organizer(s): David M. Margolis, Satya Dandekar and Susana T. Valente
Date: March 20 - 24, 2016
Location: Resort at Squaw Creek, Olympic Valley, CA, USA
Sponsored by Gilead Sciences, Inc., Merck & Co., Inc. and Sangamo BioSciences, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
Despite the clinical success of antiretroviral therapy (ART), every day there are more people newly infected with HIV than those initiating ART. The complexities of dispensing lifelong ART for HIV-infected individuals make it imperative to develop strategies for HIV eradication, or at least to strictly control the virus without daily therapy. The clearance of a retroviral infection is a herculean task and requires unraveling the mechanisms of viral persistence and host immune interactions. Further, ART does not appear to completely mitigate the impact of HIV infection on human health, and a better understanding of the overt and subtle immune pathologies induced by HIV infection is needed. Recent studies of early therapeutic interventions and HIV-resistant cellular therapies have provided new insights into the development of HIV eradication strategies. The meeting will focus on all aspects of HIV persistence and eradication that include: (1) The understanding of persistent HIV infection; (2) Innate defenses against retroviral infection; (3) The interplay of the host inflammatory response and HIV pathogenesis; and (4) Novel concepts for viral eradication. Special attention will be paid to progress in the development of model systems to study latent infection as well as strategies to eradicate it. Emphasis will be placed on new, unpublished findings that will highlight novel insights and creative strategies to develop effective control and eradication of HIV infection.
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Bill & Melinda Gates FoundationGilead Sciences, Inc.Merck & Co., Inc.Sangamo BioSciences, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Merck & Co., Inc.

Merck Research Laboratories
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI123008-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 20 | 4:00PM - 8:00PM
Arrival and Registration
Room: Lobby Alcove


Sunday, March 20 | 6:00PM - 8:00PM
Welcome Mixer
Room: Cascades
No registration fees are used to fund alcohol served at this function.

Monday, March 21 | 7:00AM - 8:00AM
Breakfast
Room: Cascades


Monday, March 21 | 8:00AM - 9:00AM
Welcome and Keynote Address (Joint)
Room: Grand Sierra Ballroom

Speaker 1 of 3
* David M. Margolis, University of North Carolina at Chapel Hill, USA

Monday, March 21 | 8:00AM - 9:00AM
Welcome and Keynote Address (Joint)
Room: Grand Sierra Ballroom

Speaker 2 of 3
* Carl W. Dieffenbach, NIAID, National Institutes of Health, USA

Monday, March 21 | 8:00AM - 9:00AM
Welcome and Keynote Address (Joint)
Room: Grand Sierra Ballroom

Speaker 3 of 3
Anthony S. Fauci, NIAID, National Institutes of Health, USA
Recorded Presentation: Ending the HIV/AIDS Pandemic: Follow the Science

Monday, March 21 | 9:00AM - 11:30AM
Acute HIV Infection and Initial Transmission Events (Joint)
Room: Grand Sierra Ballroom
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.
Speaker 1 of 6
* Nilu Goonetilleke, University of North Carolina at Chapel Hill, USA

Monday, March 21 | 9:00AM - 11:30AM
Acute HIV Infection and Initial Transmission Events (Joint)
Room: Grand Sierra Ballroom
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.
Speaker 2 of 6
George M. Shaw, University of Pennsylvania, USA
Novel SHIV Design to Recapitulate HIV-1 Transmission, Persistence and Pathogenesis and as a Guide for Vaccine and Cure Research

Monday, March 21 | 9:00AM - 11:30AM
Acute HIV Infection and Initial Transmission Events (Joint)
Room: Grand Sierra Ballroom
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.
Speaker 3 of 6
Joseph Eron, University of North Carolina School of Medicine, USA
Acute HIV Infection: Antiretroviral Therapy and Persistence

Monday, March 21 | 9:00AM - 11:30AM
Acute HIV Infection and Initial Transmission Events (Joint)
Room: Grand Sierra Ballroom
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.
Speaker 4 of 6
Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland
Novel Therapeutic Interventions in the Targeting of the HIV Cell Reservoir

Monday, March 21 | 9:00AM - 11:30AM
Acute HIV Infection and Initial Transmission Events (Joint)
Room: Grand Sierra Ballroom
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.
Speaker 5 of 6
Zachary S. Ende, Centers for Disease Control and Prevention, USA
Short Talk: Heterosexual Transmission of Subtype C HIV-1 Does Not Require Increased Replicative Capacity or Interferon Resistance

Monday, March 21 | 9:00AM - 11:30AM
Acute HIV Infection and Initial Transmission Events (Joint)
Room: Grand Sierra Ballroom
This session aims to provide new information on the biology of HIV-1 transmission and the window of opportunity for intervention.
Speaker 6 of 6
Shilpa Iyer, University of Pennsylvania, USA
Short Talk: Mucosal Transmission of HIV-1 Selects for Variants with Enhanced Infectivity, Replication Fitness and Interferon Resistance

Monday, March 21 | 9:40AM - 10:00AM
Coffee Break
Room: Sierra Prefunction


Monday, March 21 | 11:30AM - 1:00PM
Poster Setup
Room: Alpine Ballroom


Monday, March 21 | 11:30AM - 5:00PM
On Own for Lunch


Monday, March 21 | 11:45AM - 12:45PM
DAIDS Programmatic Agendas, Recent Review Policy Updates, an
d Grantsmanship Advice (Joint)
Room: Grand Sierra Ballroom
The workshop will consist of four presentations and a question and answer period at the end. Presentation topics: 1. The Persistence and Cure Agenda; 2. HIV Vaccine Initiatives; 3. Overview of Recent Policy Updates on Rigor and Reproducibly; and 4. Tips for Writing NIH Career (K) and Investigator Initiated (R01/R21) Grant Applications.

Monday, March 21 | 1:00PM - 10:00PM
Poster Viewing
Room: Alpine Ballroom


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 1 of 8
* Pamela J. Bjorkman, California Institute of Technology, USA


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 2 of 8
Matthew D. Gray, Fred Hutchinson Cancer Research Center, USA
Self-assembling HIV Envelope Nanoparticles Increase Antibody Binding, Membrane Dynamics and B-cell Activation


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 3 of 8
Christina Guzzo, NIAID, National Institutes of Health, USA
Critical Role of V2 Sulfotyrosines in Stabilizing the HIV-1 Envelope Trimer in Its Closed, Antibody-Protected Conformation


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 4 of 8
Colin Havenar-Daughton, Vir Biotechnology, USA
Virtual Immunization with eOD-GT8: Probing the Human Naive B Cell Repertoire to a Candidate HIV Vaccine Immunogen


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 5 of 8
Cassandra Simonich, Fred Hutchinson Cancer Research Center, USA
An Infant bNAb with Low Somatic Hypermutation Contributes to Polyclonal Breadth


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 6 of 8
Lorena S. Ver, IAVI, International Aids Vaccine Initiative, USA
Characterization of Neutralizing Antibody Responses to the N332 Site of Vulnerability on HIV Env in IAVI Protocol C Cohort


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 7 of 8
Amelia Escolano, Rockefeller University, USA
Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Human Ig Knock-in Mice


Monday, March 21 | 2:30PM - 4:30PM
Workshop 1: Requirements for bnAb Induction
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 8 of 8
Daniela Fera, Swarthmore College, USA
Structural Analysis of an HIV-1 Broadly Neutralizing B-Cell Lineage Targeting the Env N332 Glycan


Monday, March 21 | 4:30PM - 5:00PM
Coffee Available
Room: Sierra Prefunction


Monday, March 21 | 5:00PM - 7:15PM
Mechanisms of Persistent Infection
Room: Grand Sierra Ballroom C-D

Speaker 1 of 5
* Steven G. Deeks, University of California, San Francisco, USA

Monday, March 21 | 5:00PM - 7:15PM
Mechanisms of Persistent Infection
Room: Grand Sierra Ballroom C-D

Speaker 2 of 5
Jonathan Karn, Case Western Reserve University, USA
Epigenetic Control of HIV Latency

Monday, March 21 | 5:00PM - 7:15PM
Mechanisms of Persistent Infection
Room: Grand Sierra Ballroom C-D

Speaker 3 of 5
Melanie M. Ott, Gladstone Institutes, USA
Epigenetic Regulation of HIV Latency

Monday, March 21 | 5:00PM - 7:15PM
Mechanisms of Persistent Infection
Room: Grand Sierra Ballroom C-D

Speaker 4 of 5
Susana T. Valente, Scripps Florida, USA
Eradication without Reactivation


Monday, March 21 | 5:00PM - 7:15PM
Mechanisms of Persistent Infection
Room: Grand Sierra Ballroom C-D

Speaker 5 of 5
Andrew P. Rice, Baylor College of Medicine, USA
Regulation of P-TEFb and HIV Latency

Monday, March 21 | 5:00PM - 7:15PM
Immunologic Correlates of Sterilizing Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.
Speaker 1 of 6
* Mark Connors, NIAID, National Institutes of Health, USA


Monday, March 21 | 5:00PM - 7:15PM
Immunologic Correlates of Sterilizing Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.
Speaker 2 of 6
Merlin L. Robb, Walter Reed Army Institute of Research, USA
Optimizing Quality and Durability of Immune Responses: Insights from RV 144 Follow-up Studies


Monday, March 21 | 5:00PM - 7:15PM
Immunologic Correlates of Sterilizing Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.
Speaker 3 of 6
Genoveffa Franchini, NCI, National Institutes of Health, USA
Activated RAS in PBMCs and Extracellular Vesicle, Mucosal Envelope Antibody to V2, and Innate Lymphoid Cells are Associated with Vaccine-Mediated Reduced Risk of SIVmac251 Acquisition


Monday, March 21 | 5:00PM - 7:15PM
Immunologic Correlates of Sterilizing Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.
Speaker 4 of 6
Georgia D. Tomaras, Duke University Medical Center, USA
HIV-1 Vaccine Humoral Immunity, Immune Correlates and Mechanistic Insights


Monday, March 21 | 5:00PM - 7:15PM
Immunologic Correlates of Sterilizing Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.
Speaker 5 of 6
Genevieve Fouda, Duke University Medical Center, USA
Short Talk: HIV Exposed Infants Vaccinated with a rgp120/MF59 Vaccine have Higher Magnitude anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine


Monday, March 21 | 5:00PM - 7:15PM
Immunologic Correlates of Sterilizing Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will review what is know about the types of immune responses that have potential to prevent the acquisition of HIV-1 infection, with an emphasis on non-neutralizing antibodies.
Speaker 6 of 6
Thomas Musich, Armed Forces Research Institute of Medical Sciences, Thailand
Short Talk: Vaccine-Induced Effects on Neutrophils in Rhesus Macaques


Monday, March 21 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Cascades/Alpine Ballroom
No registration fees are used to fund alcohol served at this function.

Monday, March 21 | 7:30PM - 10:00PM
Poster Session 1
Room: Alpine Ballroom


Tuesday, March 22 | 7:00AM - 8:00AM
Breakfast
Room: Cascades


Tuesday, March 22 | 8:00AM - 11:15AM
Reservoirs and Persistence I
Room: Grand Sierra Ballroom C-D

Speaker 1 of 7
* Susana T. Valente, Scripps Florida, USA

Tuesday, March 22 | 8:00AM - 11:15AM
Reservoirs and Persistence I
Room: Grand Sierra Ballroom C-D

Speaker 2 of 7
Janice E. Clements, Johns Hopkins University, USA
Tissue Reservoirs of CD4+T Cells and Macrophages in ART Suppressed SIV-Infected Macaques

Tuesday, March 22 | 8:00AM - 11:15AM
Reservoirs and Persistence I
Room: Grand Sierra Ballroom C-D

Speaker 3 of 7
Satya Dandekar, University of California, Davis, USA
Early Establishment of HIV Reservoirs

Tuesday, March 22 | 8:00AM - 11:15AM
Reservoirs and Persistence I
Room: Grand Sierra Ballroom C-D

Speaker 4 of 7
John M. Coffin, Tufts University, USA
Mechanism of HIV Persistence despite Suppressive Antiretroviral Therapy

Tuesday, March 22 | 8:00AM - 11:15AM
Reservoirs and Persistence I
Room: Grand Sierra Ballroom C-D

Speaker 5 of 7
J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA
In vivo Analysis of HIV Persistence

Tuesday, March 22 | 8:00AM - 11:15AM
Reservoirs and Persistence I
Room: Grand Sierra Ballroom C-D

Speaker 6 of 7
Sara Ferrando-Martinez, NIAID, National Institutes of Health, USA
Short Talk: Immune Activation Drives Accumulation of Follicular CTL during Chronic HIV/SIV Infection

Tuesday, March 22 | 8:00AM - 11:15AM
Reservoirs and Persistence I
Room: Grand Sierra Ballroom C-D

Speaker 7 of 7
Binhua Ling, Tulane National Primate Research Center, USA
Short Talk: Gut Viral Reservoirs in SIV-Infected Long-Term Nonprogressing Chinese Rhesus Macaques on Antiretroviral Therapy

Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 1 of 8
* Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands


Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 2 of 8
Pamela J. Bjorkman, California Institute of Technology, USA
Structure-Based Design of Improved Antibodies Against HIV


Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 3 of 8
Sasha Murrell, The Scripps Research Institute, USA
Short Talk: Crystal Structures of Two Related Broadly Neutralizing Antibodies against the N332 Supersite in HIV Env


Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 4 of 8
Marit van Gils, Amsterdam UMC, Netherlands
Short Talk: Broadly Neutralizing Antibodies from an Elite Neutralizer Target a Novel Site at the gp120-gp41 Interface


Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 5 of 8
Dennis R. Burton, The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Guide HIV Vaccine Design


Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 6 of 8
Jinal Nomathemba Bhiman, The Scripps Research Institute, USA
Viral Variants that Initiate and Drive Maturation of Broadly Neutralizing Antibodies


Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 7 of 8
William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Epitope-Focused HIV Vaccine Design


Tuesday, March 22 | 8:00AM - 11:30AM
Epitopes, Structures and Ontogeny of Broadly Neutralizing An
tibodies
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to review what is currently known about broadly neutralizing antibodies as it relates to HIV-1 vaccine design. It will provide a molecular and immunologic basis for the two later sessions on Vaccine Concepts.
Speaker 8 of 8
Christina Yacoob, Fred Hutchinson Cancer Research Center, USA
Short Talk: Selective Allelic Expansion of HIV-1 Immunized Rhesus Macaques Based on Different Antigenic Properties of Env Immunogens


Tuesday, March 22 | 9:20AM - 9:40AM
Coffee Break
Room: Sierra Prefunction


Tuesday, March 22 | 11:15AM - 1:00PM
Poster Setup
Room: Alpine Ballroom


Tuesday, March 22 | 11:15AM - 2:30PM
On Own for Lunch


Tuesday, March 22 | 1:00PM - 2:30PM
Hands-On Computer Session on Los Alamos Sequence Database
This session is from HIV Vaccines
Room: Monument Peak
Shared computers will be supplied for the first 60 attendees. Interested participants may sign up for the meeting on a first-come, first-serve basis. If attendance is over 60 people you will be asked to bring your own computer.


Tuesday, March 22 | 1:00PM - 10:00PM
Poster Viewing
Room: Alpine Ballroom


Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 1 of 9
* Romas Geleziunas, Gilead Sciences, Inc., USA

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 2 of 9
Kirston M. Barton, University of Sydney, Australia
HIV-1 in the Blood and Intestine Contribute to Viremia During Treatment Interruption

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 3 of 9
Ya-Chi Ho, Yale School of Medicine, USA
Activation of Novel Splice Donor Sites Allows Production of tat and rev Transcripts in Defective Patient-Derived HIV-1 Proviruses

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 4 of 9
Lillian B. Cohn, Chan Zuckerberg Biohub, USA
HIV DNA Integration Site Selection in Productive Infection

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 5 of 9
Allison Thomas, George Washington University, USA
After Long-Term ART, T-cell Responses Targeting Early HIV Proteins Uniquely Correlate with Infected Cell Frequencies

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 6 of 9
Luca Micci, Emory University, YNPRC, USA
Determinants of Viral Control following ART-interruption in SIV-infected Rhesus Macaques

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 7 of 9
James L. Riley, University of Pennsylvania, USA
Engineering Chimeric Antigen Receptors for Durable Control over HIV-1 Replication

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 8 of 9
Maud Mavigner, Emory University, USA
Reducing HIV Persistence by Targeting Stem Cell Properties of Memory CD4+ T-cells

Tuesday, March 22 | 2:30PM - 4:30PM
Workshop 1: Challenges of Persistent HIV Infection
Room: Grand Sierra Ballroom C-D

Speaker 9 of 9
Angela Wahl, University of North Carolina at Chapel Hill, USA
CD4+ Tissue-Resident Memory T Cells are an Important Reservoir for HIV Persistence

Tuesday, March 22 | 4:30PM - 5:00PM
Coffee Available
Room: Sierra Prefunction


Tuesday, March 22 | 5:00PM - 7:00PM
Auxillary Genes and Host Restriction Factors
Room: Grand Sierra Ballroom C-D

Speaker 1 of 5
* J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA

Tuesday, March 22 | 5:00PM - 7:00PM
Auxillary Genes and Host Restriction Factors
Room: Grand Sierra Ballroom C-D

Speaker 2 of 5
Alan N. Engelman, Dana-Farber Cancer Institute, USA
CPSF6 Regulates HIV-1 Integration into Active Chromatin

Tuesday, March 22 | 5:00PM - 7:00PM
Auxillary Genes and Host Restriction Factors
Room: Grand Sierra Ballroom C-D

Speaker 3 of 5
Stephen P. Goff, Columbia University, USA
Retroviral Silencing: Transcriptional and Post-Transcriptional Regulation

Tuesday, March 22 | 5:00PM - 7:00PM
Auxillary Genes and Host Restriction Factors
Room: Grand Sierra Ballroom C-D

Speaker 4 of 5
Michael Emerman, Fred Hutchinson Cancer Research Center, USA
Evolution of Host Antiviral Restriction Factors

Tuesday, March 22 | 5:00PM - 7:00PM
Auxillary Genes and Host Restriction Factors
Room: Grand Sierra Ballroom C-D

Speaker 5 of 5
Richard Apps, NCI, National institutes of Health, USA
Short Talk: HIV-1 Immune Evasion by Downregulation of HLA-C

Tuesday, March 22 | 5:00PM - 7:15PM
Vaccine Concepts I
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will be in two parts and aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 1 of 5
David C. Montefiori, Duke University Medical Center, USA
Standardized Assessments of HIV Vaccine-Elicited Neutralizing Antibodies


Tuesday, March 22 | 5:00PM - 7:15PM
Vaccine Concepts I
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will be in two parts and aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 2 of 5
* Mario Roederer, NIAID, National Institutes of Health, USA
The SIV Model to Evaluate Antibody-Based Intervention


Tuesday, March 22 | 5:00PM - 7:15PM
Vaccine Concepts I
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will be in two parts and aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 3 of 5
Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Using Neutralization Resistance/Sensitivity Signatures to Inform Vaccine Design


Tuesday, March 22 | 5:00PM - 7:15PM
Vaccine Concepts I
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will be in two parts and aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 4 of 5
Javier Guenaga, IAVI Neutralizing Antibody Center at TSRI, USA
Short Talk: Display of the HIV-1 Env MPER in the Context of a Well-ordered Soluble Uncleaved (NFL) Trimer


Tuesday, March 22 | 5:00PM - 7:15PM
Vaccine Concepts I
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session will be in two parts and aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 5 of 5
James Mark Binley, San Diego Biomedical Research Institute, USA
Short Talk: Eliciting Tier 2 anti-HIV-1 NAbs using Native, Membrane Trimers


Tuesday, March 22 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Cascades/Alpine Ballroom
No registration fees are used to fund alcohol served at this function.

Tuesday, March 22 | 7:30PM - 10:00PM
Poster Session 2
Room: Alpine Ballroom


Wednesday, March 23 | 7:00AM - 8:00AM
Breakfast
Room: Cascades


Wednesday, March 23 | 8:00AM - 11:15AM
Antiviral Host Response and Inflammation
Room: Grand Sierra Ballroom C-D

Speaker 1 of 7
* Satya Dandekar, University of California, Davis, USA

Wednesday, March 23 | 8:00AM - 11:15AM
Antiviral Host Response and Inflammation
Room: Grand Sierra Ballroom C-D

Speaker 2 of 7
Nicolas Chomont, Université de Montréal, Canada
Immune Checkpoint Molecules and HIV Persistence during ART

Wednesday, March 23 | 8:00AM - 11:15AM
Antiviral Host Response and Inflammation
Room: Grand Sierra Ballroom C-D

Speaker 3 of 7
Alberto Bosque, George Washington University, USA
Short Talk: Targeting Pathogen Recognition Receptors to Reactivate Latent HIV-1

Wednesday, March 23 | 8:00AM - 11:15AM
Antiviral Host Response and Inflammation
Room: Grand Sierra Ballroom C-D

Speaker 4 of 7
Ivona Pandrea, University of Pittsburgh, USA
Nonhuman Primate Studies with Relevance for Cure Research

Wednesday, March 23 | 8:00AM - 11:15AM
Antiviral Host Response and Inflammation
Room: Grand Sierra Ballroom C-D

Speaker 5 of 7
David Favre, GlaxoSmithKline, USA
Immune Modulation as a Strategy to Clear Persistent Infection

Wednesday, March 23 | 8:00AM - 11:15AM
Antiviral Host Response and Inflammation
Room: Grand Sierra Ballroom C-D

Speaker 6 of 7
Heinrich Gottlinger, University of Massachusetts Medical School, USA
Short Talk: SERINC3 and SERINC5 Synergistically Inhibit HIV-1 Infectivity and are Antagonized by Nef

Wednesday, March 23 | 8:00AM - 11:15AM
Antiviral Host Response and Inflammation
Room: Grand Sierra Ballroom C-D

Speaker 7 of 7
Catherine A. Blish, Stanford University School of Medicine, USA
Short Talk: NK Cell Response

Wednesday, March 23 | 8:00AM - 11:15AM
Pathways Leading to Long-Term Protective Immunity Against HI
V-1
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
Speaker 1 of 7
* Jay A. Berzofsky, NCI, National Institutes of Health, USA


Wednesday, March 23 | 8:00AM - 11:15AM
Pathways Leading to Long-Term Protective Immunity Against HI
V-1
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
Speaker 2 of 7
Bali Pulendran, Stanford University School of Medicine, USA
Signaling Mechanisms


Wednesday, March 23 | 8:00AM - 11:15AM
Pathways Leading to Long-Term Protective Immunity Against HI
V-1
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
Speaker 3 of 7
William Ballou, GlaxoSmithKline, USA
Inducing Long-Term Protection with Vaccines


Wednesday, March 23 | 8:00AM - 11:15AM
Pathways Leading to Long-Term Protective Immunity Against HI
V-1
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
Speaker 4 of 7
Richard A. Koup, NIAID, National Institutes of Health, USA
T Cell Help


Wednesday, March 23 | 8:00AM - 11:15AM
Pathways Leading to Long-Term Protective Immunity Against HI
V-1
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
Speaker 5 of 7
Maria Blasi, Duke University School of Medicine, USA
Use of Integrase Defective Lentiviral Vectors Expressing HIV-Envs to Induce Durable Immune Responses


Wednesday, March 23 | 8:00AM - 11:15AM
Pathways Leading to Long-Term Protective Immunity Against HI
V-1
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
Speaker 6 of 7
Jinghe Huang, NIAID, National Institutes of Health, USA
Short Talk: Intranasal Replication Competent Adenovirus Type 4-Influenza-H5 (Ad4-H5-Vtn) Vaccine Induces Durable Neutralizing Antibody Responses in Humans


Wednesday, March 23 | 8:00AM - 11:15AM
Pathways Leading to Long-Term Protective Immunity Against HI
V-1
This session is from HIV Vaccines

Room: Grand Sierra Ballroom A-B
This session aims to address the requirements for broadly neutralizing antibody induction at the cellular level.
Speaker 7 of 7
Konstantin Virnik, Food and Drug Administration, USA
Short Talk: Expression of HIV and SIV Env Proteins in a Highly Immunogenic Rubella Vaccine Platform


Wednesday, March 23 | 9:20AM - 9:40AM
Coffee Break
Room: Sierra Prefunction


Wednesday, March 23 | 11:15AM - 1:00PM
Poster Setup
Room: Alpine Ballroom


Wednesday, March 23 | 11:15AM - 2:30PM
On Own for Lunch


Wednesday, March 23 | 1:00PM - 2:30PM
Hands-On Computer Session on Los Alamos Immunology Database
This session is from HIV Vaccines
Room: Monument Peak
Shared computers will be supplied for the first 60 attendees. Interested participants may sign up for the meeting on a first-come, first-serve basis. If attendance is over 60 people you will be asked to bring your own computer.


Wednesday, March 23 | 1:00PM - 10:00PM
Poster Viewing
Room: Alpine Ballroom


Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 1 of 9
* Karl Salzwedel, NIAID, National Institutes of Health, USA

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 2 of 9
Collin Kieffer, University of Illinois at Urbana-Champaign, USA
Longitudinal Imaging of Early HIV infection in Humanized Mice with Parallel 3D Immunofluorescence and Electron Microscopy

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 3 of 9
Bonnie J. Howell, Merck & Co., Inc., USA
Ultrasensitive Detection of Viral p24 following Reactivation of Latent HIV

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 4 of 9
Tram N.Q. Pham, Institut de Recherches Cliniques de Montreal, Canada
Enhancing Tethering of HIV Virions by BST2/Tetherin Augments the Susceptibility of Productively and Latently Infected T Cells to ADCC Mediated by Broadly Neutralizing Anti-HIV Antibodies

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 5 of 9
Yik Lim Kok, University Hospital Zurich, Switzerland
A Novel HIV-1-Based Vector that Reproduces Features of Productive and Latent HIV-1 Infections

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 6 of 9
Julia Sung, University of North Carolina, USA
HIV specific Ex vivo Expanded T Cell (HXTC) Therapy to Target the Latent Reservoir

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 7 of 9
Kenneth M. Law, Icahn School of Medicine at Mount Sinai, USA
Cell-to-cell HIV-1 Transmission Promotes Multicopy Micro-Compartmentalized Infection in Humanized Mice

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 8 of 9
Lydie Trautmann, US Military HIV Research Program, USA
Differentiation of Effector CD8 T Cells Toward Short Lived Cells Lacking Memory Potential During Acute HIV Infection

Wednesday, March 23 | 2:30PM - 4:30PM
Workshop 2: New Technologies and Approaches
Room: Grand Sierra Ballroom C-D

Speaker 9 of 9
Sarah DiNapoli, NIAID, National Institutes of Health, USA
Lymphoid Tissue-Resident Myeloid Cells Contain Replication-Competent Virus that is Genetically Similar to Virus from CD4+ T Cells in ARV-Naïve Asian Macaques

Wednesday, March 23 | 4:30PM - 5:00PM
Coffee Available
Room: Sierra Prefunction


Wednesday, March 23 | 5:00PM - 7:00PM
Cure Studies in Models and Man
Room: Grand Sierra Ballroom C-D

Speaker 1 of 5
* Carl W. Dieffenbach, NIAID, National Institutes of Health, USA

Wednesday, March 23 | 5:00PM - 7:00PM
Cure Studies in Models and Man
Room: Grand Sierra Ballroom C-D

Speaker 2 of 5
Daria J. Hazuda, Merck Research Laboratories, USA
HIV Latency Drug Discovery: Optimizing Drugs to Induce Latent HIV Expression

Wednesday, March 23 | 5:00PM - 7:00PM
Cure Studies in Models and Man
Room: Grand Sierra Ballroom C-D

Speaker 3 of 5
John W. Mellors, University of Pittsburgh School of Medicine, USA
Biomarkers of HIV Persistence and Response to Therapeutic Interventions

Wednesday, March 23 | 5:00PM - 7:00PM
Cure Studies in Models and Man
Room: Grand Sierra Ballroom C-D

Speaker 4 of 5
Jerome A. Zack, University of California, Los Angeles, USA
Synthetic PKC Modulators as HIV Latency Reversing Agents

Wednesday, March 23 | 5:00PM - 7:00PM
Cure Studies in Models and Man
Room: Grand Sierra Ballroom C-D

Speaker 5 of 5
Lucy Dorrell, University of Oxford, UK
Short Talk: Elimination of HIV-1 Reservoir Cells from Antiretroviral Therapy-Suppressed Subjects by Engineered Immune-Mobilising Dual Affinity T cell Receptors

Wednesday, March 23 | 5:00PM - 7:15PM
Vaccine Concepts II
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 1 of 6
* Bette Tina Marie Korber, Los Alamos National Laboratory, USA


Wednesday, March 23 | 5:00PM - 7:15PM
Vaccine Concepts II
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 2 of 6
John P. Moore, Weill Medical College of Cornell University, USA
How to Make and Use Multiple Native-Like SOSIP Trimers for Vaccine and Structural Studies


Wednesday, March 23 | 5:00PM - 7:15PM
Vaccine Concepts II
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 3 of 6
Barton F. Haynes, Duke University Medical Center, USA
B Cell Lineage Immunogen Design Approach to Elicit HIV Broadly Neutralizing Antibodies


Wednesday, March 23 | 5:00PM - 7:15PM
Vaccine Concepts II
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 4 of 6
Peter D. Kwong, NIAID, National Institutes of Health, USA
Structure-Based Immunogen Design


Wednesday, March 23 | 5:00PM - 7:15PM
Vaccine Concepts II
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 5 of 6
Marzena Pazgier, Uniformed Services University of the Health Sciences, USA
Short Talk: Paring down HIV-1 Env: Design and Structure of an Independent Inner Domain of gp120 Stably Expressing the A32 ADCC Epitope Sub-region


Wednesday, March 23 | 5:00PM - 7:15PM
Vaccine Concepts II
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This is the second part of a two-part series that aims to provide cutting-edge new information on progress toward a vaccine that elicits broadly neutralizing antibodies.
Speaker 6 of 6
Talar Tokatlian, Massachusetts Institute of Technology, USA
Short Talk: Design and Characterization of gp140 Envelope Trimer-Coupled Liposomes for an HIV Vaccine


Wednesday, March 23 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Cascades/Alpine Ballroom
No registration fees are used to fund alcohol served at this function.

Wednesday, March 23 | 7:30PM - 10:00PM
Poster Session 3
Room: Alpine Ballroom


Thursday, March 24 | 7:00AM - 8:00AM
Breakfast
Room: Cascades


Thursday, March 24 | 7:30AM - 8:00AM
Poster Setup
Room: Alpine Ballroom


Thursday, March 24 | 8:00AM - 3:00PM
Poster Viewing
Room: Alpine Ballroom


Thursday, March 24 | 8:00AM - 8:45AM
Keynote Address (Joint)
Room: Grand Sierra Ballroom

Speaker 1 of 2
* David C. Montefiori, Duke University Medical Center, USA

Thursday, March 24 | 8:00AM - 8:45AM
Keynote Address (Joint)
Room: Grand Sierra Ballroom

Speaker 2 of 2
John R. Mascola, NIAID, National Institutes of Health, USA
Active and Passive Antibody-Based Immunity to HIV-1

Thursday, March 24 | 8:45AM - 11:45AM
Immunotherapy (Joint)
Room: Grand Sierra Ballroom
This session aims to address the potential value of antibodies in the treatment and cure of HIV-1 infection.
Speaker 1 of 5
* Michael Seaman, Beth Israel Deaconess Medical Center-Harvard Medical School, USA

Thursday, March 24 | 8:45AM - 11:45AM
Immunotherapy (Joint)
Room: Grand Sierra Ballroom
This session aims to address the potential value of antibodies in the treatment and cure of HIV-1 infection.
Speaker 2 of 5
David D. Ho, Aaron Diamond AIDS Research Center (ADARC), Columbia University Medical Center, USA
Bispecific Antibodies

Thursday, March 24 | 8:45AM - 11:45AM
Immunotherapy (Joint)
Room: Grand Sierra Ballroom
This session aims to address the potential value of antibodies in the treatment and cure of HIV-1 infection.
Speaker 3 of 5
Michael Farzan, The Scripps Research Institute, USA
AAV-Expressed eCD4-Ig as an Alternative HIV-1 Vaccine

Thursday, March 24 | 8:45AM - 11:45AM
Immunotherapy (Joint)
Room: Grand Sierra Ballroom
This session aims to address the potential value of antibodies in the treatment and cure of HIV-1 infection.
Speaker 4 of 5
David M. Margolis, University of North Carolina at Chapel Hill, USA
Enlisting Effector Cells to Clear Latent HIV Infection

Thursday, March 24 | 8:45AM - 11:45AM
Immunotherapy (Joint)
Room: Grand Sierra Ballroom
This session aims to address the potential value of antibodies in the treatment and cure of HIV-1 infection.
Speaker 5 of 5
Louis J. Picker, Oregon Health & Science University, USA
CMV-Based HIV Vaccines for HIV Prevention and Clearance

Thursday, March 24 | 9:30AM - 9:50AM
Coffee Break
Room: Sierra Prefunction


Thursday, March 24 | 11:45AM - 12:45PM
Lunch
Room: Cascades


Thursday, March 24 | 12:00PM - 2:30PM
Poster Session 4
Room: Alpine Ballroom


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 1 of 9
* Diane L. Bolton, US Military HIV Research Program, WRAIR, USA


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 2 of 9
Nina Rafterman Derby, Population Council, USA
HSV-2 Infection Increases Rectal SIV?Nef Infection and May Reduce Vaccine Effect


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 3 of 9
Shelby O'Connor, University of Wisconson-Madison, USA
Tracking SIV Infection and Viral Evolution in vivo using a Barcoded Virus Stock


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 4 of 9
Hadia Mohammad Mohammad, University of Minnesota, USA
CTL-Based Vaccine-Induced Protection is Associated with Induction of High Follicular to Extra-Follicular Ratios of Virus-Specific CD8 T Cells


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 5 of 9
Namal Liyanage, Ohio State University, College of Medicine, USA
Recruitment of Vaccine Induced MMucosal IL17+NKp44+Innate Lymphoid Cells (ILCs) to Decrease the Risk of SIVmac251 Acquisition in Macaques


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 6 of 9
M. Anthony Moody, Duke University Medical Center, USA
Vaccine-Induced Anatomic Distribution of Env-Specific B Cell Repertoires: Implications for the Genesis of Induced Mucosal Antibodies in Rhesus Macaques


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 7 of 9
George M. Shaw, University of Pennsylvania, USA


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 8 of 9
Jay A. Berzofsky, NCI, National Institutes of Health, USA
Immune Activation and the Microbiome in Mucosal Transmission of SHIV


Thursday, March 24 | 2:30PM - 4:30PM
Workshop 2: NHP Models for HIV Vaccines
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B

Speaker 9 of 9
Donald Forthal, University of California, Irvine, USA
Non-Neutralizing Antibodies Reduce the Rate of SIVmac251 Infection Following Low-Dose Repeated Penile Challenge


Thursday, March 24 | 4:30PM - 5:00PM
Coffee Available
Room: Sierra Prefunction


Thursday, March 24 | 5:00PM - 6:45PM
Reservoirs and Persistence II
Room: Grand Sierra Ballroom C-D

Speaker 1 of 4
* Douglas D. Richman, University of California, San Diego, USA

Thursday, March 24 | 5:00PM - 6:45PM
Reservoirs and Persistence II
Room: Grand Sierra Ballroom C-D

Speaker 2 of 4
Sarah E. Palmer, University of Sydney, Australia
Characterizing the HIV-1 Reservoir During Long-Term Therapy

Thursday, March 24 | 5:00PM - 6:45PM
Reservoirs and Persistence II
Room: Grand Sierra Ballroom C-D

Speaker 3 of 4
Vicente Planelles, University of Utah, USA
Novel Classes of HIV Latency-Reversing Agents

Thursday, March 24 | 5:00PM - 6:45PM
Reservoirs and Persistence II
Room: Grand Sierra Ballroom C-D

Speaker 4 of 4
Nancie M. Archin, University of North Carolina at Chapel Hill, USA
Updates on in vivo Administration of Vorinostat

Thursday, March 24 | 5:00PM - 6:45PM
Bridging Innate and Acquired Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session aims to emphasize the potential importance of non-neutralizing antibodies and their mechanisms.
Speaker 1 of 4
* Nicole Frahm, Bill & Melinda Gates Medical Research Institute, USA


Thursday, March 24 | 5:00PM - 6:45PM
Bridging Innate and Acquired Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session aims to emphasize the potential importance of non-neutralizing antibodies and their mechanisms.
Speaker 2 of 4
Stylianos Bournazos, Rockefeller University, USA
Optimizing Antibody-FcR Interactions


Thursday, March 24 | 5:00PM - 6:45PM
Bridging Innate and Acquired Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session aims to emphasize the potential importance of non-neutralizing antibodies and their mechanisms.
Speaker 3 of 4
Margaret E. Ackerman, Dartmouth College, USA
Profiling Protective Antibody Responses


Thursday, March 24 | 5:00PM - 6:45PM
Bridging Innate and Acquired Immunity
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B
This session aims to emphasize the potential importance of non-neutralizing antibodies and their mechanisms.
Speaker 4 of 4
George K. Lewis, University of Maryland, USA
Qualitative and Quantitative Variables that Contribute to Fc-mediated Protection Against HIV-1


Thursday, March 24 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Grand Sierra Ballroom C-D


Thursday, March 24 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from HIV Vaccines
Room: Grand Sierra Ballroom A-B


Thursday, March 24 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Cascades/Alpine Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, March 24 | 8:00PM - 11:00PM
Entertainment
Room: Cascades/Alpine Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 24 | 8:00PM - 11:00PM
Cash Bar
Room: Cascades/Alpine Ballroom


Friday, March 25 | 10:25AM - 10:25AM
Departure


*Session Chair.